← Back to Search

JAK Inhibitor

CTP-543 8 mg BID for Alopecia Areata (THRIVE-AA1 Trial)

Phase 3
Waitlist Available
Research Sponsored by Concert Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 4, 8, 12, 16, 20, and 24
Awards & highlights

THRIVE-AA1 Trial Summary

This study is evaluating whether an investigational drug may help treat hair loss.

Eligible Conditions
  • Alopecia Areata

THRIVE-AA1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 4, 8, 12, 16, 20, and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 4, 8, 12, 16, 20, and 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24
Secondary outcome measures
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
+12 more

THRIVE-AA1 Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: PlaceboExperimental Treatment1 Intervention
Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
Group II: CTP-543 8 mg BIDExperimental Treatment1 Intervention
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
Group III: CTP-543 12 mg BIDPlacebo Group1 Intervention
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CTP-543
2021
Completed Phase 3
~2110
CTP-543 matching placebo
2020
Completed Phase 3
~1380

Find a Location

Who is running the clinical trial?

Concert PharmaceuticalsLead Sponsor
34 Previous Clinical Trials
3,705 Total Patients Enrolled
7 Trials studying Alopecia Areata
2,513 Patients Enrolled for Alopecia Areata

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Virginia
Pennsylvania
Florida
Other
How old are they?
65+
18 - 65
What site did they apply to?
Lenus Research & Medical Group, LLC
Forward Clinical Trials Inc.
University of Pennsylvania
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
2020. "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04518995.
~163 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top